| Prevalence of Parkinson's disease across North America |
89 |
| Modeling Parkinson's disease in midbrain-like organoids |
42 |
| Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease |
32 |
| Cognitive impairment in Parkinson's disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health |
22 |
| Proteasome-targeted nanobodies alleviate pathology and functional decline in an alpha-synuclein-based Parkinson's disease model |
19 |
| Mitochondrial dysfunction within the synapses of substantia nigra neurons in Parkinson's disease |
16 |
| Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson's disease heritability |
15 |
| Cognitive training for freezing of gait in Parkinson's disease: a randomized controlled trial |
15 |
| Risk factors of levodopa-induced dyskinesia in Parkinson's disease: results from the PPMI cohort |
15 |
| NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson's disease |
15 |
| Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson's disease |
13 |
| Mitochondria function associated genes contribute to Parkinson's Disease risk and later age at onset |
12 |
| Altered dopamine release and monoamine transporters in Vps35 p.D620N knock-in mice |
12 |
| Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease |
11 |
| Parkinson's progression prediction using machine learning and serum cytokines |
11 |
| Infection with mosquito-borne alphavirus induces selective loss of dopaminergic neurons, neuroinflammation and widespread protein aggregation |
11 |
| Rhythmic abilities and musical training in Parkinson's disease: do they help? |
11 |
| Caregiver burden and caregiver appraisal of psychiatric symptoms are not modulated by subthalamic deep brain stimulation for Parkinson's disease |
10 |
| Detection of endogenous S1292 LRRK2 autophosphorylation in mouse tissue as a readout for kinase activity |
10 |
| 'Levodopa Phobia': a review of a not uncommon and consequential phenomenon |
8 |
| Freezing of Gait can persist after an acute levodopa challenge in Parkinson's disease |
8 |
| Management of constipation in patients with Parkinson's disease |
8 |
| Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let's talk about the lipids in the room |
8 |
| Monitoring Parkinson's disease symptoms during daily life: a feasibility study |
7 |
| State-level prevalence, health service use, and spending vary widely among Medicare beneficiaries with Parkinson disease |
7 |
| Objective measurement in routine care of people with Parkinson's disease improves outcomes |
7 |
| Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota |
7 |
| The Parkinson's phenome-traits associated with Parkinson's disease in a broadly phenotyped cohort |
6 |
| Ingestion of subthreshold doses of environmental toxins induces ascending Parkinsonism in the rat |
6 |
| In vivo imaging of inflammation and oxidative stress in a nonhuman primate model of cardiac sympathetic neurodegeneration |
6 |
| Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder |
6 |
| Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson's disease |
6 |
| Optimizing olfactory testing for the diagnosis of Parkinson's disease: item analysis of the university of Pennsylvania smell identification test |
6 |
| The use of accelerometry as a tool to measure disturbed nocturnal sleep in Parkinson's disease |
5 |
| Outcomes from deep brain stimulation targeting subthalamic nucleus and caudal zona incerta for Parkinson's disease |
4 |
| Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression |
4 |
| Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial |
4 |
| Changes in Parkinson's disease sleep symptoms and daytime somnolence after bilateral subthalamic deep brain stimulation in Parkinson's disease |
4 |
| Deep brain stimulation and genetic variability in Parkinson's disease: a review of the literature |
4 |
| 24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson's disease |
3 |
| Antibody biomarker for de novo Parkinson disease: attempted validation |
3 |
| Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease |
3 |
| Contractile dysfunction and nitrergic dysregulation in small intestine of a primate model of Parkinson's disease |
3 |
| Loss of glutamate signaling from the thalamus to dorsal striatum impairs motor function and slows the execution of learned behaviors |
3 |
| Differentiating cognitive or motor dimensions associated with the perception of fall-related self-efficacy in Parkinson's disease |
2 |
| Vertical saccades and antisaccades: complementary markers for motor and cognitive impairment in Parkinson's disease |
2 |
| Validation of a simple screening tool for early diagnosis of advanced Parkinson's disease in daily practice: the CDEPA questionnaire |
2 |
| Optimizing Parkinson's disease diagnosis: the role of a dual nuclear imaging algorithm |
2 |
| Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics |
2 |
| Differential contributions of subthalamic beta rhythms and 1/f broadband activity to motor symptoms in Parkinson's disease |
2 |
